AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...
Johnson & Johnson
Johnson & Johnson Completes Spinoff of Kenvue as Independent Company
Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its...
European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma
The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...
J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment
The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar
US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement...
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter...
Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority
United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging...
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...
Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from...
Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions
Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...
Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma
The Janssen subsidiary of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an additional indication...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...
CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China
The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...
Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering...
Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma
China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...